Dmitry Khasak, MD
Dermatology · New York, NYNPI 1649258286
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.1% of the total across 723 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 16.3% — the pattern of someone who eats at a lot of different presentations.
Across 723 payments — averaging $25.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dermavant Sciences, Inc.$3K
- AbbVie$2K
- Johnson & Johnson$2K
- Regeneron Healthcare Solutions, Inc.$1K
- Sun Pharmaceutical Industries Inc.$1K
- Ortho Dermatologics, A Division Of Bausch Health US, LLC$1K
- plus $8K from 32 others
What the payments were for
- Food & beverage$18,23697%
- Education$5543%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dermavant Sciences, Inc. | 45 | $3,056 |
| AbbVie | 62 | $2,237 |
| Johnson & Johnson | 69 | $1,918 |
| Regeneron Healthcare Solutions, Inc. | 46 | $1,171 |
| Sun Pharmaceutical Industries Inc. | 44 | $1,109 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 69 | $1,077 |
| Amgen | 41 | $957 |
| Arcutis Biotherapeutics, Inc. | 42 | $832 |
| E.r. Squibb & Sons, L.L.C. | 32 | $785 |
| Incyte Corporation | 37 | $781 |
| Almirall LLC | 36 | $671 |
| Sanofi | 31 | $591 |
| Galderma Laboratories, L.p. | 26 | $588 |
| Pfizer | 39 | $582 |
| Mayne Pharma Commercial LLC | 20 | $285 |
| Journey Medical Corporation | 7 | $283 |
| UCB, Inc. | 13 | $265 |
| Smith+Nephew | 15 | $253 |
| Organon | 3 | $207 |
| LEO Pharma Inc. | 7 | $149 |
| Lilly USA, LLC | 7 | $142 |
| EPI Health, LLC | 4 | $132 |
| VYNE Pharmaceuticals Inc. | 5 | $112 |
| Novartis | 5 | $107 |
| Teva Pharmaceuticals USA, Inc. | 1 | $105 |
| Sanofi-aventis U.S. LLC | 1 | $80 |
| Botanix SB Inc | 2 | $41 |
| Phadia US Inc. | 2 | $39 |
| Melinta Therapeutics, LLC | 2 | $38 |
| Cipher Pharmaceuticals US LLC | 1 | $35 |
| Bristol Myers Squibb | 2 | $28 |
| Exact Sciences | 1 | $25 |
| Boehringer Ingelheim | 1 | $23 |
| Shield Therapeutics Inc | 1 | $19 |
| Genentech USA, Inc. | 1 | $19 |
| Encore Dermatology Inc. | 1 | $18 |
| Medimetriks Pharmaceuticals, Inc. | 1 | $16 |
| Promius Pharma LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,790 in reported general payments places this provider in the 85th percentile of 1,151 dermatology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 265 | $973,789 |
| OpzeluraRuxolitinib Phosphate | 399 | $786,987 |
| SkyriziRisankizumab-Rzaa | 21 | $421,092 |
| Everolimus | 16 | $412,054 |
| StelaraUstekinumab | 15 | $335,708 |
| Tavaborole | 534 | $333,927 |
| OtezlaApremilast | 66 | $314,704 |
| Dupixent PenDupilumab | 68 | $251,904 |
| Humira(Cf) PenAdalimumab | 13 | $179,439 |
| ZoryveRoflumilast | 194 | $162,063 |
| OlumiantBaricitinib | 51 | $153,907 |
| Pimecrolimus | 468 | $122,758 |
| SoriluxCalcipotriene | 71 | $116,270 |
| Tacrolimus | 558 | $113,166 |
| VtamaTapinarof | 82 | $112,349 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationOpzelura | $781 | $786,987399 claims |
| AbbVieSkyrizi | $2,237 | $421,09221 claims |
| Johnson & JohnsonStelara | $1,918 | $335,70815 claims |
| AmgenOtezla | $957 | $314,70466 claims |
| Arcutis Biotherapeutics, Inc.Zoryve | $832 | $162,063194 claims |
| Lilly USA, LLCOlumiant | $142 | $153,90751 claims |
| PfizerCibinqo, Eucrisa | $582 | $125,61683 claims |
| Dermavant Sciences, Inc.Vtama | $3,056 | $112,34982 claims |
| E.r. Squibb & Sons, L.L.C.Sotyktu | $785 | $96,71715 claims |
| Ortho Dermatologics, A Division Of Bausch Health US, LLCJublia | $1,077 | $80,41789 claims |
| Almirall LLCKlisyri | $671 | $52,31949 claims |
| VYNE Pharmaceuticals Inc.Zilxi | $112 | $30,99068 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,151 dermatology providers in New York.
Other dermatology in New York
- Alexandra GolantNew York$3.6M
- David CohenNew York$3M
- Michael CameronNew York$2.6M
- Saakshi KhattriNew York$2.4M
- Amy WechslerNew York$2.4M
- Joshua ZeichnerNew York$2.1M
- Emma GuttmanNew York$1.7M
- George HanNew York$1.6M
- Amy SpizuocoNew York$1.3M
- Andrew AlexisNew York$834K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.